Rafael Holdings Business Summary

Rafael Holdings, Inc. (RFL) operates as a diversified holding company that generates revenue through a dual-segment model comprising commercial real estate and healthcare-focused investments. The Real Estate segment produces consistent cash flow via rental income from its Newark, New Jersey headquarters, which includes office space and a data center. The Healthcare segment functions as a strategic investment platform, holding equity stakes and royalty interests in clinical-stage biotechnology firms, most notably Cyclo Therapeutics and the Barer Institute, focusing on oncology and rare diseases. RFL’s business model is characterized by a "hub-and-spoke" investment strategy, where it provides capital and management oversight to early-stage ventures in exchange for future milestone and licensing revenue. Compared to direct competitors such as Roivant Sciences, BridgeBio Pharma, and Alexandria Real Estate Equities, Rafael Holdings occupies a unique micro-cap niche, blending the stability of tangible property assets with the high-alpha potential of a biotech venture capital portfolio. The company is anchored by Founder and Chairman Howard Jonas, a seasoned telecommunications and energy mogul who previously founded IDT Corporation and Genie Energy. The executive team is led by Chief Executive Officer Bill Rice, who possesses over three decades of experience in clinical research and corporate leadership within the oncology sector, and Chief Financial Officer David Polinsky, a specialist in pharmaceutical law and corporate finance who co-founded several life science entities. The Board of Directors includes influential industry figures such as Michael Weiss, the Chairman and CEO of TG Therapeutics, lending significant institutional credibility to the firm’s clinical investment decisions. This leadership core leverages a deep network in both the financial and scientific communities to identify distressed or undervalued healthcare assets, maintaining a lean corporate structure designed to maximize shareholder value through strategic divestitures and spin-offs.